Dose-effect relationship of rilmenidine after chronic administration View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1993-09

AUTHORS

R. Luccioni, M. Lambert, P. Ambrosi, M. Scemama

ABSTRACT

The antihypertensive efficacy and acceptability of 3 doses of rilmenidine (0.5, 1 and 2 mg, once daily) and a placebo over a 4 week period have been compared in a randomised, double-blind, parallel-group trial in 60 mild to moderate hypertensive patients. Six patients dropped out: 4 in the 2 mg-group and one in the 1 mg-group because of adverse events, and one in the placebo group for personal reason. The blood pressure was significantly decreased after the 1 and 2 mg doses with the maximum antihypertensive effect already being obtained after 1 mg. A significant dose-effect relationship was shown for supine systolic blood pressure (P=0.05) but not for the supine diastolic blood pressure.The most beneficial efficacy/acceptability ratio was achieved at the dose of 1 mg once daily, which demonstrated the maximum antihypertensive effect associated with a low incidence of adverse events. More... »

PAGES

157-160

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00315498

DOI

http://dx.doi.org/10.1007/bf00315498

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1009988622

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/8223838


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Pressure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rilmenidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Supine Position", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, CHU la Timone, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "Department of Cardiology, CHU la Timone, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Luccioni", 
        "givenName": "R.", 
        "id": "sg:person.01245004127.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245004127.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, CHU la Timone, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "Department of Cardiology, CHU la Timone, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lambert", 
        "givenName": "M.", 
        "id": "sg:person.01022243753.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022243753.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, CHU la Timone, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "Department of Cardiology, CHU la Timone, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ambrosi", 
        "givenName": "P.", 
        "id": "sg:person.01223374503.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223374503.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "IRIS, Courbevoie, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "IRIS, Courbevoie, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scemama", 
        "givenName": "M.", 
        "type": "Person"
      }
    ], 
    "datePublished": "1993-09", 
    "datePublishedReg": "1993-09-01", 
    "description": "The antihypertensive efficacy and acceptability of 3 doses of rilmenidine (0.5, 1 and 2 mg, once daily) and a placebo over a 4 week period have been compared in a randomised, double-blind, parallel-group trial in 60 mild to moderate hypertensive patients. Six patients dropped out: 4 in the 2 mg-group and one in the 1 mg-group because of adverse events, and one in the placebo group for personal reason. The blood pressure was significantly decreased after the 1 and 2 mg doses with the maximum antihypertensive effect already being obtained after 1 mg. A significant dose-effect relationship was shown for supine systolic blood pressure (P=0.05) but not for the supine diastolic blood pressure.The most beneficial efficacy/acceptability ratio was achieved at the dose of 1 mg once daily, which demonstrated the maximum antihypertensive effect associated with a low incidence of adverse events.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf00315498", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "45"
      }
    ], 
    "keywords": [
      "maximum antihypertensive effect", 
      "dose-effect relationship", 
      "blood pressure", 
      "antihypertensive effect", 
      "adverse events", 
      "supine systolic blood pressure", 
      "supine diastolic blood pressure", 
      "parallel-group trial", 
      "doses of rilmenidine", 
      "moderate hypertensive patients", 
      "significant dose-effect relationship", 
      "systolic blood pressure", 
      "diastolic blood pressure", 
      "antihypertensive efficacy", 
      "placebo group", 
      "hypertensive patients", 
      "chronic administration", 
      "low incidence", 
      "rilmenidine", 
      "patients", 
      "week period", 
      "doses", 
      "personal reasons", 
      "group", 
      "placebo", 
      "incidence", 
      "dose", 
      "administration", 
      "trials", 
      "efficacy", 
      "pressure", 
      "events", 
      "effect", 
      "acceptability", 
      "period", 
      "relationship", 
      "reasons", 
      "ratio", 
      "beneficial efficacy/acceptability ratio", 
      "efficacy/acceptability ratio", 
      "acceptability ratio"
    ], 
    "name": "Dose-effect relationship of rilmenidine after chronic administration", 
    "pagination": "157-160", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1009988622"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00315498"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "8223838"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00315498", 
      "https://app.dimensions.ai/details/publication/pub.1009988622"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_231.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf00315498"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00315498'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00315498'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00315498'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00315498'


 

This table displays all metadata directly associated to this object as RDF triples.

182 TRIPLES      21 PREDICATES      82 URIs      74 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00315498 schema:about N15ed529df2684d0da4b4199ac1f0f015
2 N2eb77eea6cc64d868c76a4c8b559aa91
3 N32e2ac14e5664c15ae5726048c6bbee9
4 N33560edeee464f08bde26a4b245c19a2
5 N7872394efb1543569a919562a5fb250c
6 N78884ed1339347bdbdeedfb15246a940
7 N7bfa93bea05b4e958596d475abc6b298
8 N7c8e737c46724a8f921e5ae372cb87d0
9 N854e930cac654290b999e517b56aff49
10 N8673922847cd4296b5f04ef2bd1a0c71
11 N9d74dde98d7a4749bcb753c91e161255
12 Na42b3adc296f4346bf22ef146f226d8b
13 Nb337798fef4a460a8c03be6c8c0ce910
14 Nbc5740d31fb34bacad02d2ff6c2161da
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author Naaee431df3dd424e8ed65ab92774374d
18 schema:datePublished 1993-09
19 schema:datePublishedReg 1993-09-01
20 schema:description The antihypertensive efficacy and acceptability of 3 doses of rilmenidine (0.5, 1 and 2 mg, once daily) and a placebo over a 4 week period have been compared in a randomised, double-blind, parallel-group trial in 60 mild to moderate hypertensive patients. Six patients dropped out: 4 in the 2 mg-group and one in the 1 mg-group because of adverse events, and one in the placebo group for personal reason. The blood pressure was significantly decreased after the 1 and 2 mg doses with the maximum antihypertensive effect already being obtained after 1 mg. A significant dose-effect relationship was shown for supine systolic blood pressure (P=0.05) but not for the supine diastolic blood pressure.The most beneficial efficacy/acceptability ratio was achieved at the dose of 1 mg once daily, which demonstrated the maximum antihypertensive effect associated with a low incidence of adverse events.
21 schema:genre article
22 schema:inLanguage en
23 schema:isAccessibleForFree false
24 schema:isPartOf N107b29d0ab7d4bbc99db1461bc269ffa
25 N908034d0b07c40eeaf931bb75531df86
26 sg:journal.1054337
27 schema:keywords acceptability
28 acceptability ratio
29 administration
30 adverse events
31 antihypertensive effect
32 antihypertensive efficacy
33 beneficial efficacy/acceptability ratio
34 blood pressure
35 chronic administration
36 diastolic blood pressure
37 dose
38 dose-effect relationship
39 doses
40 doses of rilmenidine
41 effect
42 efficacy
43 efficacy/acceptability ratio
44 events
45 group
46 hypertensive patients
47 incidence
48 low incidence
49 maximum antihypertensive effect
50 moderate hypertensive patients
51 parallel-group trial
52 patients
53 period
54 personal reasons
55 placebo
56 placebo group
57 pressure
58 ratio
59 reasons
60 relationship
61 rilmenidine
62 significant dose-effect relationship
63 supine diastolic blood pressure
64 supine systolic blood pressure
65 systolic blood pressure
66 trials
67 week period
68 schema:name Dose-effect relationship of rilmenidine after chronic administration
69 schema:pagination 157-160
70 schema:productId N07553db3f49449b5ad91a4d5e25fdb6a
71 Ne48d298a06de4b3897b07082e76da5b1
72 Nfc83a30fac5c47ce8cbad26ee2a35743
73 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009988622
74 https://doi.org/10.1007/bf00315498
75 schema:sdDatePublished 2022-01-01T18:05
76 schema:sdLicense https://scigraph.springernature.com/explorer/license/
77 schema:sdPublisher Ncf50a2efbdb340899b7f2235767b6782
78 schema:url https://doi.org/10.1007/bf00315498
79 sgo:license sg:explorer/license/
80 sgo:sdDataset articles
81 rdf:type schema:ScholarlyArticle
82 N07553db3f49449b5ad91a4d5e25fdb6a schema:name pubmed_id
83 schema:value 8223838
84 rdf:type schema:PropertyValue
85 N107b29d0ab7d4bbc99db1461bc269ffa schema:issueNumber 2
86 rdf:type schema:PublicationIssue
87 N15ed529df2684d0da4b4199ac1f0f015 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Male
89 rdf:type schema:DefinedTerm
90 N2eb77eea6cc64d868c76a4c8b559aa91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Hypertension
92 rdf:type schema:DefinedTerm
93 N32e2ac14e5664c15ae5726048c6bbee9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Double-Blind Method
95 rdf:type schema:DefinedTerm
96 N33560edeee464f08bde26a4b245c19a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Dose-Response Relationship, Drug
98 rdf:type schema:DefinedTerm
99 N3d1e4bf9980f4d4694d2592101d7e266 rdf:first Nc895b25d0d994f6397783ef067350fe5
100 rdf:rest rdf:nil
101 N5a9a10b0474540c8845e829e754329da rdf:first sg:person.01223374503.82
102 rdf:rest N3d1e4bf9980f4d4694d2592101d7e266
103 N5d7e5fc5c1474bb0bed0a9471175e142 rdf:first sg:person.01022243753.45
104 rdf:rest N5a9a10b0474540c8845e829e754329da
105 N7872394efb1543569a919562a5fb250c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Drug Administration Schedule
107 rdf:type schema:DefinedTerm
108 N78884ed1339347bdbdeedfb15246a940 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Oxazoles
110 rdf:type schema:DefinedTerm
111 N7bfa93bea05b4e958596d475abc6b298 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Rilmenidine
113 rdf:type schema:DefinedTerm
114 N7c8e737c46724a8f921e5ae372cb87d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Middle Aged
116 rdf:type schema:DefinedTerm
117 N854e930cac654290b999e517b56aff49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Female
119 rdf:type schema:DefinedTerm
120 N8673922847cd4296b5f04ef2bd1a0c71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Antihypertensive Agents
122 rdf:type schema:DefinedTerm
123 N908034d0b07c40eeaf931bb75531df86 schema:volumeNumber 45
124 rdf:type schema:PublicationVolume
125 N9d74dde98d7a4749bcb753c91e161255 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Blood Pressure
127 rdf:type schema:DefinedTerm
128 Na42b3adc296f4346bf22ef146f226d8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Supine Position
130 rdf:type schema:DefinedTerm
131 Naaee431df3dd424e8ed65ab92774374d rdf:first sg:person.01245004127.96
132 rdf:rest N5d7e5fc5c1474bb0bed0a9471175e142
133 Nb337798fef4a460a8c03be6c8c0ce910 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Heart Rate
135 rdf:type schema:DefinedTerm
136 Nbc5740d31fb34bacad02d2ff6c2161da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Humans
138 rdf:type schema:DefinedTerm
139 Nc895b25d0d994f6397783ef067350fe5 schema:affiliation grid-institutes:None
140 schema:familyName Scemama
141 schema:givenName M.
142 rdf:type schema:Person
143 Ncf50a2efbdb340899b7f2235767b6782 schema:name Springer Nature - SN SciGraph project
144 rdf:type schema:Organization
145 Ne48d298a06de4b3897b07082e76da5b1 schema:name dimensions_id
146 schema:value pub.1009988622
147 rdf:type schema:PropertyValue
148 Nfc83a30fac5c47ce8cbad26ee2a35743 schema:name doi
149 schema:value 10.1007/bf00315498
150 rdf:type schema:PropertyValue
151 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
152 schema:name Medical and Health Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
155 schema:name Clinical Sciences
156 rdf:type schema:DefinedTerm
157 sg:journal.1054337 schema:issn 0031-6970
158 1432-1041
159 schema:name European Journal of Clinical Pharmacology
160 schema:publisher Springer Nature
161 rdf:type schema:Periodical
162 sg:person.01022243753.45 schema:affiliation grid-institutes:grid.411266.6
163 schema:familyName Lambert
164 schema:givenName M.
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022243753.45
166 rdf:type schema:Person
167 sg:person.01223374503.82 schema:affiliation grid-institutes:grid.411266.6
168 schema:familyName Ambrosi
169 schema:givenName P.
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223374503.82
171 rdf:type schema:Person
172 sg:person.01245004127.96 schema:affiliation grid-institutes:grid.411266.6
173 schema:familyName Luccioni
174 schema:givenName R.
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245004127.96
176 rdf:type schema:Person
177 grid-institutes:None schema:alternateName IRIS, Courbevoie, France
178 schema:name IRIS, Courbevoie, France
179 rdf:type schema:Organization
180 grid-institutes:grid.411266.6 schema:alternateName Department of Cardiology, CHU la Timone, Marseille, France
181 schema:name Department of Cardiology, CHU la Timone, Marseille, France
182 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...